



CS/NSE&BSE/BM/2019-20
April 15, 2019

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Stock Code: 530239

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Stock Code: SUVEN-EQ

Dear Sir/Madam,

Sub: Outcome of the Board Meeting
Ref: Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

.....

With reference to the above subject, please note that the Board of Directors of the company, at its meeting held today i.e. 15th April, 2019, has taken on record and approved the following matter(s).

- 1) Approved the enhancement of investment limits in WOS in USA Suven Neurosciences, Inc. from USD 25 Million upto USD 50 Million to undertake clinical trials on the molecules in the pipeline.
- 2) As per the policy approved by the Board, the information on the grant of product patents to the company and periodical updates thereon will be available henceforth on our Company's website only. Since grant of product patents per se is not material information to be notified hence the Company is discontinuing forthwith the issue of News Releases to the Stock Exchanges.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com